MELBOURNE, Australia, May 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference, on Wednesday 8th May. The next Emerging Growth Conference will be presented on Wednesday, 8 May, 2024. This live, interactive online event will give existing sharehol ...

MELBOURNE, Australia, May 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference, on Wednesday 8th May. The next Emerging Growth Conference will be presented on Wednesday, 8 May, 2024. This live, interactive online event will give existing sharehol ...

MELBOURNE, Australia, May 03, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Stephen Anastasiou has resigned from his position as Non-Executive Director effective today to focus on his other business interests. Stephen has served as a Director since 2013 and has provided valued contributions and experienced counsel to the Company. During Stephen's tenure, Immuron launched Travelan® into the USA and Canadi ...

销售额数据 - Immuron Limited在2024年3月份的销售额达到了3.6百万澳元，同比增长了154%[1] - 公司在全球市场的销售额在2024年3月份达到了1.3百万澳元，同比增长了51%[1] - Travelan®的销售额在澳大利亚市场2024年3月份达到了0.9百万澳元，同比增长了66%[2] - Immuron在美国市场的Travelan®销售额在2024年3月份达到了0.8百万澳元，同比增长了35%[4] 市场趋势 - 澳大利亚统计局报告显示，2024年1月份短期居民返回率比2023年同期增长了27%[3] 领导者观点 - 公司首席商务官Flavio Palumbo表示，对Travelan®的销售成绩感到兴奋，希望在北美市场的投资和分销能够带来品牌的增长[5]

Exhibit 99.1 Immuron Limited Appendix 4D Half-year 31 December 2023 Name of entity: Immuron Limited ABN: 80 063 114 045 Half-year ended: 31 December 2023 Previous period: 31 December 2022 Results for announcement to the market $ Revenue from ordinary activities Up 303.6% to 2,355,580 Net loss after tax (from ordinary activities) for the period attributable to members Up (4.8)% to (2,073,182) Net loss after tax for the period attributable to members Up (4.8)% to (2,073,182) Net tangible assets per security 3 ...

Exhibit 99.1 Corporate Governance Immuron Limited and its Board of Directors are committed to implementing and achieving an effective corporate governance framework. Our Corporate Governance Statement can be found on our website at www.immuron.com.au. Content Chairman’s letter 3 Review of operations and activities 5 Form 20-F 8 Consolidated Financial Statements 103 Auditor’s Independence Declaration 175 Independent Auditor’s Report 176 Shareholder Information 181 Corporate Directory 183 Annual Report 2023 2 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...

Exhibit 99.1 Immuron Limited Appendix 4D Half-year 31 December 2022 Name of entity: Immuron Limited ABN: 80 063 114 045 Half-year ended: 31 December 2022 Previous period: 31 December 2021 Results for announcement to the market $ Revenue from ordinary activities Up 152.7% to 583,646 Net loss after tax (from ordinary activities) for the period attributable to members Up (9.2)% to (1,978,383) Net loss after tax for the period attributable to members Up (9.2)% to (1,978,383) Net tangible assets per security 31 ...